These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 10962573

  • 41. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
    Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, Ronen SM.
    J Natl Cancer Inst; 2003 Nov 05; 95(21):1624-33. PubMed ID: 14600095
    [Abstract] [Full Text] [Related]

  • 42. Altered states: selectively drugging the Hsp90 cancer chaperone.
    Workman P.
    Trends Mol Med; 2004 Feb 05; 10(2):47-51. PubMed ID: 15106614
    [Abstract] [Full Text] [Related]

  • 43. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.
    Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla KN, Wu J.
    Mol Cancer Ther; 2005 Sep 05; 4(9):1311-9. PubMed ID: 16170022
    [Abstract] [Full Text] [Related]

  • 44. Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor.
    Yu W, Wang J, Jin J, Qian W, Qian J, Cheng Y, Wang L.
    Leuk Res; 2011 Sep 05; 35(9):1212-8. PubMed ID: 21632108
    [Abstract] [Full Text] [Related]

  • 45. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.
    Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, Kanda Y, Akinaga S, Soga S, Shiotsu Y.
    Clin Cancer Res; 2010 May 15; 16(10):2792-802. PubMed ID: 20406843
    [Abstract] [Full Text] [Related]

  • 46. The Hsp90 chaperone complex as a novel target for cancer therapy.
    Goetz MP, Toft DO, Ames MM, Erlichman C.
    Ann Oncol; 2003 Aug 15; 14(8):1169-76. PubMed ID: 12881371
    [Abstract] [Full Text] [Related]

  • 47. Regulation of glucocorticoid receptor steroid binding and trafficking by the hsp90/hsp70-based chaperone machinery: implications for clinical intervention.
    Murphy PJ.
    Leukemia; 2005 May 15; 19(5):710-2. PubMed ID: 15759036
    [No Abstract] [Full Text] [Related]

  • 48. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.
    Sain N, Krishnan B, Ormerod MG, De Rienzo A, Liu WM, Kaye SB, Workman P, Jackman AL.
    Mol Cancer Ther; 2006 May 15; 5(5):1197-208. PubMed ID: 16731752
    [Abstract] [Full Text] [Related]

  • 49. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
    Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N.
    Clin Cancer Res; 2002 May 15; 8(5):986-93. PubMed ID: 12006510
    [Abstract] [Full Text] [Related]

  • 50. Nm23-H1 metastasis suppressor expression level influences the binding properties, stability, and function of the kinase suppressor of Ras1 (KSR1) Erk scaffold in breast carcinoma cells.
    Salerno M, Palmieri D, Bouadis A, Halverson D, Steeg PS.
    Mol Cell Biol; 2005 Feb 15; 25(4):1379-88. PubMed ID: 15684389
    [Abstract] [Full Text] [Related]

  • 51. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.
    Burger AM, Fiebig HH, Stinson SF, Sausville EA.
    Anticancer Drugs; 2004 Apr 15; 15(4):377-87. PubMed ID: 15057143
    [Abstract] [Full Text] [Related]

  • 52. Hsp90: an emerging target for breast cancer therapy.
    Beliakoff J, Whitesell L.
    Anticancer Drugs; 2004 Aug 15; 15(7):651-62. PubMed ID: 15269596
    [Abstract] [Full Text] [Related]

  • 53. ITZ-1, a client-selective Hsp90 inhibitor, efficiently induces heat shock factor 1 activation.
    Kimura H, Yukitake H, Tajima Y, Suzuki H, Chikatsu T, Morimoto S, Funabashi Y, Omae H, Ito T, Yoneda Y, Takizawa M.
    Chem Biol; 2010 Jan 29; 17(1):18-27. PubMed ID: 20142037
    [Abstract] [Full Text] [Related]

  • 54. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.
    Sanderson S, Valenti M, Gowan S, Patterson L, Ahmad Z, Workman P, Eccles SA.
    Mol Cancer Ther; 2006 Mar 29; 5(3):522-32. PubMed ID: 16546966
    [Abstract] [Full Text] [Related]

  • 55. Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin.
    Nguyen DM, Chen A, Mixon A, Schrump DS.
    J Thorac Cardiovasc Surg; 1999 Nov 29; 118(5):908-15. PubMed ID: 10534697
    [Abstract] [Full Text] [Related]

  • 56. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Holmes JL, Sharp SY, Hobbs S, Workman P.
    Cancer Res; 2008 Feb 15; 68(4):1188-97. PubMed ID: 18281495
    [Abstract] [Full Text] [Related]

  • 57. 17-AAG: mechanisms of antitumour activity.
    Konstantinopoulos PA, Papavassiliou AG.
    Expert Opin Investig Drugs; 2005 Dec 15; 14(12):1471-4. PubMed ID: 16307487
    [Abstract] [Full Text] [Related]

  • 58. Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.
    Huntoon CJ, Nye MD, Geng L, Peterson KL, Flatten KS, Haluska P, Kaufmann SH, Karnitz LM.
    Cancer Res; 2010 Nov 01; 70(21):8642-50. PubMed ID: 20841485
    [Abstract] [Full Text] [Related]

  • 59. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.
    Castro JE, Prada CE, Loria O, Kamal A, Chen L, Burrows FJ, Kipps TJ.
    Blood; 2005 Oct 01; 106(7):2506-12. PubMed ID: 15972449
    [Abstract] [Full Text] [Related]

  • 60. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells.
    Fumo G, Akin C, Metcalfe DD, Neckers L.
    Blood; 2004 Feb 01; 103(3):1078-84. PubMed ID: 14551138
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.